EU Approval In View For Novavax COVID-19 Vaccine; EMA OKs Janssen Booster
Agency Also Clears Xevudy & Kineret, Advises On Use Of Pfizer's Paxlovid
Executive Summary
It’s all go on the EU coronavirus front this week: three new therapies and another vaccine booster have been recommended for use, and a special session on the Novavax vaccine is to be held at the EMA next week. More production capacity has been OKd for three vaccines.
You may also be interested in...
Immunocore Expects EU Verdict This Week On Novel TCR Immunotherapy
Pfizer’s oral COVID-19 antiviral drug and Celgene/Bristol Myers Squibb’s CAR-T for treating large B-cell lymphoma are among 11 new drugs on which the EMA is set to adopt recommendations on their possible EU-wide approval.
Coronavirus Notebook: Pfizer Files Paxlovid In EU, France Updates Treatment Advice As Omicron Proliferates
NRx Pharmaceuticals has again filed for a US emergency use authorization for aviptadil, this time for critically ill patients with no other options. The UK has said that there is currently no need to give a second booster vaccine.
UK Nod For Pfizer’s COVID-19 Oral Treatment
Pfizer’s Paxlovid is the second take-at-home COVID-19 treatment approved for use in the UK.